News

Canon Medical Systems USA Inc. Announces Expansion of Distributorship with the Acquisition of NXC Imaging

Tustin, California, (GLOBE NEWSWIRE) — Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces it has signed a definitive agreement to acquire NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota. Founded in 1964, NXC Imaging’s distributorship area spans the U.S. Upper Midwest. The acquisition is expected to close in the third quarter of the 2022 calendar year.

The addition of NXC Imaging to Canon Medical Systems USA will strengthen its sales and service channels across the Upper Midwest in Canon’s diagnostic imaging portfolio that includes modalities of Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance (MR), X-ray (XR), Vascular Imaging (VL) and Ultrasound (UL). Canon Medical plans to continue building its substantial sales and service organization, offering innovative solutions and unique business models tailored to each client’s specific needs.

“We have partnered with NXC Imaging for over 33 years,” said Yuji Hamada, CEO and President of Canon Medical Systems USA Inc. “Our successful partnership has thrived due to Canon’s innovative technology and trusting collaboration with NXC’s entrepreneurial company culture. The results of our partnership have demonstrated strong results over the past 15 years in the Upper Midwest region.”

“Our company’s foundation was built on our long-term customer relationships, trust, and loyalty in our territories. As a result, we have provided exceptional technology solutions and best-in-class support. We are proud of the legacy we’ve created and know that as a part of Canon Medical, we will continue to provide the Upper Midwest region with the same “Never Ordinary” customer service we are known for,” stated Bruce Zeilinger, President, and CEO of NXC Imaging.

Read more here.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients